Merck & Company (MRK) Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Merck & Company (MRK – Research Report) yesterday and set a price target of $155.00. The company’s shares closed yesterday at $127.99.

According to TipRanks, Chen is an analyst with an average return of -9.0% and a 39.71% success rate. Chen covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Pfizer.

In addition to Cantor Fitzgerald, Merck & Company also received a Buy from Goldman Sachs’s Chris Shibutani in a report issued on June 12. However, yesterday, Morgan Stanley maintained a Hold rating on Merck & Company (NYSE: MRK).

MRK market cap is currently $327.9B and has a P/E ratio of 141.94.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Merck & Company (MRK) Company Description:

Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.